Healthcare Equities

The companies that provide, support or coordinate medical goods and services. This sector spans a broad range of activities – including the development and manufacture of medical equipment, pharmaceuticals and other treatments. Activities range from research to manufacturing, administration, insurance and facilities management. Our Healthcare research includes healthcare services, healthcare information technology (IT), medical devices, biotechnology, biopharmaceuticals and specialty pharmaceuticals.

OSE Immunotherapeutics (PAR: OSE) and partner Veloxis Pharmaceuticals announce ODD for VEL-101 >

Arron Aatkar, PhD | Healthcare | Comment | 1 day ago

OSE Immunotherapeutics (PAR: OSE) and partner Veloxis Pharmaceuticals announce ODD for VEL-101 >

Arron Aatkar, PhD | Healthcare | Comment | 1 day ago

SEE ALL COMMENTARY >

Actinogen Medical (ACW)

Latest price

AUD0.05

— 0.00 (0.00)

As at 22/01/2026

Market capitalisation: AUD160m

Equities

Equities by Sector

Sectors

Thematics

Latest

Edison explains: Private credit demystified

Edison explains: Finfluencers – #Trending or toxic?

Hansa House View – Q425

Audiovisual

Latest

Murray International Trust – equity proposition

Baillie Gifford US Growth Trust – equity proposition

BB Biotech – executive interview

About Edison

About Edison

Careers

Healthcare Equities

Actinogen Medical (ACW)

AUD0.05

Actinogen Medical — XanaMIA passes first safety milestone

Actinogen Medical — XanaMIA recruitment exceeds expectations

Actinogen Medical — An eventful period ahead for Xanamem

See morecontent on

AFT Pharmaceuticals (AFT)

NZD3.79

AFT Pharmaceuticals — Making progress on growth strategy

AFT Pharmaceuticals — Setting the stage for sustained long-term growth

AFT Pharmaceuticals — Softer H1 on one-offs; recovery expected in H2

See morecontent on

Alzinova (ALZ)

SEK0.75

Webinar: The CNS renaissance Biotech companies at the forefront

Alzinova — Innovative new approach to Alzheimer's

See morecontent on

AOTI (AOTI)

GBP0.42

Argent Biopharma (RGT)

AUD0.06

Argent Biopharma — Valuation report

Argent Biopharma — An innovative approach to drug development

MGC Pharmaceuticals — Rapid prescription growth in Australia and the UK

See morecontent on

Basilea Pharmaceutica (BSLN)

CHF54.70

Basilea Pharmaceutica — BARDA backs latest antibacterial programme

Bull, Bear & Beyond – Basilea Pharmaceutica: executive interview

Basilea Pharmaceutica – executive interview

See morecontent on

Biomea Fusion (BMEA)

USD1.43

Biomea Fusion — An innovative approach to diabetes and obesity

See morecontent on

BioVersys (BIOV)

CHF23.50

BioVersys — Targeting resistant and threatening indications

See morecontent on

Cantargia (CANTA)

SEK6.10

Cantargia — Encouraging data for nadunolimab in CANFOUR

Cantargia — First patient treated in Phase II part of TRIFOUR

Cantargia — Next phase of clinical development in sight

See morecontent on

Cereno Scientific (CRNO-B)

SEK6.62

Cereno Scientific — Entering a value inflection phase

Cereno Scientific — Runway clears for Phase IIb with FDA nod

Cereno Scientific — Armed and ready for Phase II

See morecontent on

Chosa (CHOSA)

SEK0.95

CHOSA Oncology – executive interview

Outlook for 2024: Life sciences – where has the conviction gone?

Chosa Oncology — Making headway in precision oncology

See morecontent on

Creo Medical (CREO)

GBP0.12

Creo Medical — FY25 results validate growth strategy

Creo Medical — H1 momentum underpins FY25 confidence

Creo Medical — SpydrBlade Flex set to enter the US market

See morecontent on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on